Jellatech to Expand Bioidentical Human Collagen Production at New 9,000-Square-Foot Facility

Jellatech, a US biotech company specializing in cell-based collagen, has completed construction of a new 9,000 square-foot facility in North Carolina. This facility will enable the company to produce bioidentical collagen at scale for pre-clinical trials, essential for adopting collagen-based applications across various sectors. Jellatech aims to revolutionize biotechnology and sustainable protein production, with plans to collaborate with industry leaders to create innovative healthcare solutions.

Founded in 2020, Jellatech uses cellular agriculture to produce bio-identical bovine, porcine, and human cell-based collagen. The company has received strategic investments and funding, including a recent oversubscribed seed round. With the new facility, Jellatech looks to set new standards in sustainability, innovation, and biotechnology, while prioritizing ethically produced proteins for human health and longevity applications.